V
Vincent C. O. Njar
Researcher at University of Maryland, Baltimore
Publications - 154
Citations - 10648
Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Autophagy Inhibition Synergistically Enhances Anticancer Efficacy of RAMBA, VN/12-1 in SKBR-3 Cells, and Tumor Xenografts
Abhijit M. Godbole,Puranik Purushottamachar,Marlena S. Martin,Constantine Daskalakis,Vincent C. O. Njar +4 more
TL;DR: The novel findings suggest that VN/12-1 may be useful as a single agent or in combination with autophagy inhibitors for treating human breast cancers.
Journal ArticleDOI
Synthesis of 4-fluoroestradiol and related analogs
Patent
Anti-cancer agents and androgen inhibition activity compound
TL;DR: A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs) is used as a template in virtual screening compounds for new ARDAs.
Journal ArticleDOI
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.
Puranik Purushottamachar,Jyoti Patel,Lalji K. Gediya,Lalji K. Gediya,Omoshile O. Clement,Vincent C. O. Njar,Vincent C. O. Njar +6 more
TL;DR: The first three-dimensional (3D) pharmacophore model was developed for potent retinoidal retinoic acid metabolism blocking agents (RAMBAs) with IC(50) values ranging from 0.0009 to 5.84nM and revealed the potential of the model in identifying structurally diverse and potent RAMBAs.
Journal ArticleDOI
Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice
Andrew K. Kwegyir-Afful,Francis N. Murigi,Puranik Purushottamachar,Vidya P. Ramamurthy,Marlena S. Martin,Marlena S. Martin,Vincent C. O. Njar +6 more
TL;DR: It is shown for the first time, that gal/analogs profoundly inhibited cell viability of gem citabine-naive/resistance PDAC cell lines and strongly synergized with gemcitabine in gemcitABine-resistant PDAC cells, and these promising findings strongly support further development of gal/Analogs as novel therapeutics for PDAC.